In its Q2 2026 letter, Buffalo Mid Cap Discovery Fund said Corcept Therapeutics added to its relative performance, with the stock benefiting from improved investor confidence in the company’s commercial execution and pipeline opportunities.
The fund returned 11.34% in Q2 2026, below the Russell Midcap Growth Index’s 14.55% return, according to the letter.
Corcept closed at $118.51 on Sept. 24, 2026; the article reported a 4.07% rise over the previous month and a 41.30% gain over the year. Its database showed 30 hedge-fund portfolios held Corcept at the end of Q2, down from 41 in Q1.
